Kite and Shoreline ink allogeneic cell therapy deal worth up to $2.3 billion

Published: 21 June 2021

Partnership to develop allogeneic cell therapy candidates for leukemia and lymphoma based on Shoreline’s iPSC platform

Gilead Sciences-owned Kite and Shoreline Biosciences will work together to develop CAR natural killer (NK) cell therapies for blood cancers, with the option to expand into iPSC-derived CAR macrophage immunotherapies in the future.

Shoreline received an undisclosed upfront payment and stands to receive over $2.3 billion if development milestones are met.

“The combined strength of Kite’s leadership in CAR T-cell therapies and our cutting-edge iPSC platform will potentially accelerate Shoreline’s timeline to the clinic, expand our pipeline opportunities and deliver transformational treatment options for cancer,” said Kleanthis G. Xanthopoulos, Ph.D., Shoreline Co-Founder, Chairman, and CEO, in a press release.

In April, Shoreline completed a $43 million Series A round, with Kite as one of the investors.